Biosimilars Ineligible For Reduced Medicaid Rebates As Authorized Generics
Executive Summary
CMS reiterates and elaborates on its position that biosimilars should be subject to brand-level rebates in Medicaid, adding to the perception that the agency’s reimbursement policies do not promote development of biosimilars.
You may also be interested in...
Biosimilars Pricing In Medicare Part D Needs Legislative Fix, Avalere Says
Requiring 50% discount for biosimilars in the coverage gap or establishing biosimilar specialty tier with reduced coinsurance could encourage broader take-up, consulting firm suggests.
Doc Groups Seek To Block CMS Biosimilars Policy Via Congress
Letter from six physician organizations to Senate Finance Committee Chairman Hatch says CMS' decision to group multiple biosimilars into a single payment code undermines innovation, science and safety.
CMS Sticks With Combining Biosimilars In Single Medicare Payment Code
Biosimilars referencing the same innovator biologic will all be placed into the same billing code for Medicare, CMS says in final rule, despite opposition from biopharma manufacturers and members of Congress.